Canada first market for Crestor
October 27, 2003AstraZeneca's Crestor is to receive an immediate launch in its first market after Canada's regulator's approved the new cholesterol lowering …
Mixed Paxil patent news for GSK
October 27, 2003GlaxoSmithKline has received mixed news in the on-going patent battle with Canadian generics company Apotex over its biggest selling drug, …
Pfizer blockbuster to face competition
October 27, 2003Pfizer's blockbuster hypertension and angina treatment Norvasc could face competition from a related drug following a US court ruling.A ruling …
Private sector invited to take over failing hospitals
October 27, 2003The poorest performing NHS hospitals could now be run by private companies under new plans unveiled by the Government.Eight private …
NICE launches intervention assessment programme
October 27, 2003The safety and efficacy of new surgical and non-surgical interventions are to be assessed as part of a new NICE …
Galen boosted by $295m Sarafem purchase
October 27, 2003Galen has bolstered its product range by buying the rights to pre-menstrual syndrome treatment Sarafem from Lilly for $295 million.Shares …
Industry wins parallel import trademark case
October 24, 2003A new UK High Court ruling has given pharma companies the right to block the sale of re-packaged parallel imports …
Three companies face US fraud lawsuits
October 24, 2003Three pharmaceutical companies, GlaxoSmithKline, Pharmacia and Aventis, face legal action for alleged bribery and inflation of prescription drug prices in …
Smaller hospitals win Government support
October 24, 2003Smaller local hospitals are to become important centres for developing patient-centred care in a reversal of what the Government calls …
14 more PCTs to join pharmaceutical services revolution
October 24, 2003Fourteen PCTs have been given the go-ahead to develop new and innovative services and improve patient services through community pharmacists.Local …
J&J strengthens biotech business
October 24, 2003Janssen, Janssen Cilag, Johnson & Johnson, Scios
Johnson & Johnson is to expand its biotech capabilities with a $2.4 billion purchase of US company Scios.The deal, still …
vCJD caution prompts Serono product withdrawal
October 24, 2003Serono is to withdraw one of its hormone products from the UK after a case of variant Creutzfeldt-Jakob disease was …
Latest content
FibroFind appoints Lee Borthwick as CEO
